Literature DB >> 15458456

Progression of nephropathy in type 2 diabetic patients.

Kasper Rossing1, Per K Christensen, Peter Hovind, Lise Tarnow, Peter Rossing, Hans-Henrik Parving.   

Abstract

BACKGROUND: Nephropathy in type 2 diabetes is the single most common cause of end-stage renal disease (ESRD), but the decline in kidney function varies considerably between individuals, and determinants of renal function loss, early in the course of renal disease, have not been clearly identified.
METHODS: In a prospective observational study, we followed 227 (60 female) Caucasian type 2 diabetic patients with nephropathy for 6.5 (range 3 to 17) years from a baseline glomerular filtration rate (GFR) of 83 (SD30) mL/min/1.73m(2) with 7 (range 3 to 22) measurements of GFR ((51)Cr-EDTA) per patient. We evaluated determinants of (1) rate of decline in GFR, (2) risk of doubling in serum creatinine or ESRD, and (3) mortality using potential risk factors at baseline and during follow-up.
RESULTS: The mean (SD) rate of decline in GFR was 5.2 (4.1) mL/min/year. In multivariate regression analysis, higher baseline albuminuria, systolic blood pressure (SBP), hemoglobin A1c, GFR, age, and degree of diabetic retinopathy were significantly associated with increased rate of decline in GFR (R(2) (adj) 0.24). During follow-up, elevated mean albuminuria, SBP, hemoglobin A1c, and lower hemoglobin, heavy smoking, and presence of diabetic retinopathy were significantly associated with increased decline in GFR (R(2) (adj) 0.26). During follow-up, 63 patients had a doubling in serum creatinine or developed ESRD, and 79 patients died, primarily due to cardiovascular disease. In Cox regression analysis, higher baseline albuminuria, hemoglobin A1c, and SBP, together with lower GFR and hemoglobin, were significantly associated with shorter time to doubling of serum creatinine or ESRD. Higher baseline albuminuria, hemoglobin A1c, SBP, and age were significantly associated with increased mortality.
CONCLUSION: Our long-term prospective study of type 2 diabetic patients with nephropathy has revealed several modifiable risk factors of enhanced progression in kidney disease and increased mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458456     DOI: 10.1111/j.1523-1755.2004.00925.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  90 in total

1.  Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes.

Authors:  Salvatore De Cosmo; Antonio Minenna; Yuan-Yuan Zhang; Ryan Thompson; Robert Thompson; Giuseppe Miscio; Monica Vedovato; Anna Rauseo; Alois Saller; Sandra Mastroianno; Fabio Pellegrini; Roberto Trevisan; Paola Fioretto; Alessandro Doria; Vincenzo Trischitta
Journal:  Am J Kidney Dis       Date:  2008-10-31       Impact factor: 8.860

2.  Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.

Authors:  Tangli Xiao; Xu Guan; Ling Nie; Song Wang; Lei Sun; Ting He; Yunjian Huang; Jingbo Zhang; Ke Yang; Junping Wang; Jinghong Zhao
Journal:  Mol Cell Biochem       Date:  2014-05-22       Impact factor: 3.396

3.  Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker.

Authors:  Ghada Al-Kafaji; Ghazi Al-Mahroos; Haifa Abdulla Al-Muhtaresh; Cristina Skrypnyk; Mohamed Abdalla Sabry; Ahmad R Ramadan
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

4.  Nephrotic range proteinuria as a strong risk factor for rapid renal function decline during pre-dialysis phase in type 2 diabetic patients with severely impaired renal function.

Authors:  Yuichiro Kitai; Yohei Doi; Keisuke Osaki; Sayaka Sugioka; Masao Koshikawa; Akira Sugawara
Journal:  Clin Exp Nephrol       Date:  2015-02-15       Impact factor: 2.801

Review 5.  Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.

Authors:  Nicholas Stoycheff; Kruti Pandya; Aghogho Okparavero; Abigail Schiff; Andrew S Levey; Tom Greene; Lesley A Stevens
Journal:  Nephrol Dial Transplant       Date:  2010-09-03       Impact factor: 5.992

6.  Robust clinical marker identification for diabetic kidney disease with ensemble feature selection.

Authors:  Xing Song; Lemuel R Waitman; Yong Hu; Alan S L Yu; David C Robbins; Mei Liu
Journal:  J Am Med Inform Assoc       Date:  2019-03-01       Impact factor: 4.497

Review 7.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

8.  Silent diabetic nephropathy.

Authors:  Katia López-Revuelta; Patricia Peña Galdo; Ramona Stanescu; Leticia Parejo; Carmen Guerrero; Elia Pérez-Fernández
Journal:  World J Nephrol       Date:  2014-02-06

9.  Microalbuminuria predicts overt proteinuria among patients with HIV infection.

Authors:  L A Szczech; P Menezes; E Byrd Quinlivan; C van der Horst; J A Bartlett; L P Svetkey
Journal:  HIV Med       Date:  2010-01-04       Impact factor: 3.180

Review 10.  Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?

Authors:  Shelly Bhanot; David J Leehey
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.